Literature DB >> 9010029

Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).

E Suarez Pestana1, U Greiser, B Sánchez, L E Fernández, A Lage, R Perez, F D Böhmer.   

Abstract

Growth of the EGF receptor-expressing non-small-cell lung carcinoma cell line H125 seems to be at least partially driven by autocrine activation of the resident EGF receptors. Thus, the possibility of an EGF receptor-directed antiproliferative treatment was investigated in vitro using a monoclonal antibody (alpha EGFR ior egf/r3) against the human EGF receptor and gangliosides which are known to possess antiproliferative and anti-tyrosine kinase activity. The moderate growth-inhibitory effect of alpha EGFR ior egf/r3 was strongly potentiated by the addition of monosialoganglioside GM3. Likewise, the combination of alpha EGFR ior egf/r3 and GM3 inhibited EGF receptor autophosphorylation activity in H125 cells more strongly than either agent alone. A synergistic inhibition of EGF receptor autophosphorylation by alpha EGFR ior egf/r3 and GM3 was also observed in the human epidermoid carcinoma cell line A431. In both cell lines, the inhibition of EGF receptor autophosphorylation by GM3 was prevented by pretreatment of the cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases (PTPases). Also, GM3 accelerated EGF receptor dephosphorylation in isolated A431 cell membranes. These findings indicate that GM3 has the capacity to activate EGF receptor-directed PTPase activity and suggest a novel possible mechanism for the regulation of cellular PTPases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010029      PMCID: PMC2063275          DOI: 10.1038/bjc.1997.36

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  52 in total

1.  Synthesis and characterization of ganglioside GM3 derivatives: lyso-GM3, de-N-acetyl-GM3, and other compounds.

Authors:  G A Nores; N Hanai; S B Levery; H L Eaton; M E Salyan; S Hakomori
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

2.  Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects.

Authors:  U Rodeck; M Herlyn; D Herlyn; C Molthoff; B Atkinson; M Varello; Z Steplewski; H Koprowski
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

3.  Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture.

Authors:  N Kamata; K Chida; K Rikimaru; M Horikoshi; S Enomoto; T Kuroki
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

4.  Receptors for epidermal growth factor in human mammary carcinomas and their metastases.

Authors:  A Macias; E Azavedo; R Perez; L E Rutqvist; L Skoog
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

5.  Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas.

Authors:  A Macias; E Azavedo; T Hägerström; C Klintenberg; R Pérez; L Skoog
Journal:  Anticancer Res       Date:  1987 May-Jun       Impact factor: 2.480

6.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

7.  Identification of transforming growth factor alpha in human primary breast carcinomas.

Authors:  A Macias; R Perez; T Hägerström; L Skoog
Journal:  Anticancer Res       Date:  1987 Nov-Dec       Impact factor: 2.480

8.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.

Authors:  T J Velu; L Beguinot; W C Vass; M C Willingham; G T Merlino; I Pastan; D R Lowy
Journal:  Science       Date:  1987-12-04       Impact factor: 47.728

9.  Ganglioside-mediated modulation of cell growth. Specific effects of GM3 and lyso-GM3 in tyrosine phosphorylation of the epidermal growth factor receptor.

Authors:  N Hanai; G A Nores; C MacLeod; C R Torres-Mendez; S Hakomori
Journal:  J Biol Chem       Date:  1988-08-05       Impact factor: 5.157

10.  Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines.

Authors:  G Söderdahl; C Betsholtz; A Johansson; K Nilsson; J Bergh
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

View more
  7 in total

1.  Combinatorial PCR approach to homology-based cloning: cloning and expression of mouse and human GM3-synthase.

Authors:  D Kapitonov; E Bieberich; R K Yu
Journal:  Glycoconj J       Date:  1999-07       Impact factor: 2.916

Review 2.  Modulation of growth factor signaling by gangliosides: positive or negative?

Authors:  Karen Kaucic; Yihui Liu; Stephan Ladisch
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  Modulation of epidermal growth factor receptor phosphorylation by endogenously expressed gangliosides.

Authors:  A R Zurita; H J Maccioni; J L Daniotti
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

4.  Bronchioloalveolar carcinoma in African Americans.

Authors:  Syed Hasan; Humera Mujahid; Mahmoud Yousef; Reginald Chisholm
Journal:  J Natl Med Assoc       Date:  2004-09       Impact factor: 1.798

5.  Nanoscale analysis reveals no domain formation of glycosylphosphatidylinositol-anchored protein SAG1 in the plasma membrane of living Toxoplasma gondii.

Authors:  Yuna Kurokawa; Tatsunori Masatani; Rikako Konishi; Kanna Tomioku; Xuenan Xuan; Akikazu Fujita
Journal:  Histochem Cell Biol       Date:  2019-09-21       Impact factor: 4.304

6.  Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor.

Authors:  Mercedes Cedeño-Arias; Javier Sánchez-Ramírez; Rancés Blanco-Santana; Enrique Rengifo-Calzado
Journal:  Sci Pharm       Date:  2011-07-03

7.  Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab.

Authors:  Greta Garrido; Ailem Rabasa; Cristina Garrido; Lisset Chao; Federico Garrido; Ángel M García-Lora; Belinda Sánchez-Ramírez
Journal:  Front Pharmacol       Date:  2017-10-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.